FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($1.14), $0.06 better than the analyst estimate of ($1.20). Revenue for the quarter came in at $6.77 million versus the consensus estimate of $7.74 million.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
... More
